Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Hodgkin Disease 1

Interventions

Cyclophosphamide 172Rituximab 157Specimen Handling 116Biopsy 93Magnetic Resonance Spectroscopy 90Vincristine 89Doxorubicin 83Prednisone 81fludarabine 70venetoclax 67obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 46acalabrutinib 43Etoposide 41blinatumomab 40CT-P10 39Bendamustine Hydrochloride 37fludarabine phosphate 33Gemcitabine 33prednylidene 32Calcium Dobesilate 32deltacortene 31zanubrutinib 30pembrolizumab 29glofitamab 28Nivolumab 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematopoietic Stem Cell Mobilization × Lymphoid × 90 days × Clear all
NCT06724237 2026-05-15

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Eastern Cooperative Oncology Group

Phase 3 Recruiting
294 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
257 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡